TY - JOUR
KW - Constipation/drug therapy
KW - Double-Blind Method
KW - Guanylyl Cyclase C Agonists/pharmacology/therapeutic use
KW - Humans
KW - Peptides/pharmacology/therapeutic use
KW - Pilot Projects
KW - Chronic constipation
KW - laxatives
KW - linaclotide
KW - treatment
AU - Gabrio Bassotti
AU - Paolo Usai-Satta
AU - Massimo Bellini
A1 - 
AB - INTRODUCTION: Chronic constipation (CC) is a common gastrointestinal disorder with limited treatment options. Linaclotide is a potent peptide agonist of the guanylate cyclase-C receptor. This action activates intracellular conversion of guanosine 5-triphosphate to cyclic guanosine monophosphate resulting in the stimulation of intestinal fluid secretion. Linaclotide is a promising new agent for refractory constipation. Areas covered: All published articles regarding the development, clinical efficacy, and safety of linaclotide in treating CC were reviewed. Pharmacodynamics, pharmacokinetics, and metabolism of this secretagogue agent were examined. Clinical studies showed that linaclotide increases the number of spontaneous bowel movements and stool consistency scores. Overall, patients reported relief from abdominal discomfort and severity of constipation. Finally, linaclotide has a good safety profile, with diarrhea being the main side effect. Expert opinion: Linaclotide appears to be a well-tolerated and effective agent for patients with CC, and could be effectively combined with other drugs in patients with refractory constipation. However, data on the efficacy and safety of linaclotide in pediatric patients and in opioid-induced constipation are currently limited and more studies need to be undertaken.
AD - a Gastroenterology & Hepatology Section, Department of Medicine , University of Perugia Medical School , Perugia , Italy.; b Gastrointestinal Unit , 'P. Brotzu' Hospital , Cagliari , Italy.; c Gastrointestinal Unit, Department of Gastroenterology , University of Pisa , Pisa , Italy.
BT - Expert opinion on pharmacotherapy
C5 - Healthcare Disparities; Opioids & Substance Use
CP - 11
CY - England
DO - 10.1080/14656566.2018.1494728
IS - 11
JF - Expert opinion on pharmacotherapy
LA - eng
M1 - Journal Article
N2 - INTRODUCTION: Chronic constipation (CC) is a common gastrointestinal disorder with limited treatment options. Linaclotide is a potent peptide agonist of the guanylate cyclase-C receptor. This action activates intracellular conversion of guanosine 5-triphosphate to cyclic guanosine monophosphate resulting in the stimulation of intestinal fluid secretion. Linaclotide is a promising new agent for refractory constipation. Areas covered: All published articles regarding the development, clinical efficacy, and safety of linaclotide in treating CC were reviewed. Pharmacodynamics, pharmacokinetics, and metabolism of this secretagogue agent were examined. Clinical studies showed that linaclotide increases the number of spontaneous bowel movements and stool consistency scores. Overall, patients reported relief from abdominal discomfort and severity of constipation. Finally, linaclotide has a good safety profile, with diarrhea being the main side effect. Expert opinion: Linaclotide appears to be a well-tolerated and effective agent for patients with CC, and could be effectively combined with other drugs in patients with refractory constipation. However, data on the efficacy and safety of linaclotide in pediatric patients and in opioid-induced constipation are currently limited and more studies need to be undertaken.
PP - England
PY - 2018
SN - 1744-7666; 1465-6566
SP - 1261
EP - 1266
EP - 
T1 - Linaclotide for the treatment of chronic constipation
T2 - Expert opinion on pharmacotherapy
TI - Linaclotide for the treatment of chronic constipation
U1 - Healthcare Disparities; Opioids & Substance Use
U2 - 29985664
U3 - 10.1080/14656566.2018.1494728
VL - 19
VO - 1744-7666; 1465-6566
Y1 - 2018
Y2 - Aug
ER -